Skip to content
10-Q

Quarterly Report

NASCENT BIOTECH, INC.

0001477932-23-000947

← back to feed
Filed
Feb 14, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Feb 14, 2023 124.49M sh
Shares Diluted Q3 2023 · Dec 31, 2022 119.5M sh
Shares Diluted Q3 2023 · Dec 31, 2022 115.4M sh
Shares Diluted Q3 2023 · Dec 31, 2021 112.36M sh
Shares Diluted Q3 2023 · Dec 31, 2021 107.47M sh
Current Liabilities Q3 2023 · Dec 31, 2022 $1.93M
Current Liabilities Q3 2023 · Mar 31, 2022 $776.89K
Total Liabilities Q3 2023 · Dec 31, 2022 $1.93M
Total Liabilities Q3 2023 · Mar 31, 2022 $776.89K
Current Assets Q3 2023 · Dec 31, 2022 $565.84K
Current Assets Q3 2023 · Mar 31, 2022 $105.41K
Total Assets Q3 2023 · Dec 31, 2022 $565.84K
Total Assets Q3 2023 · Mar 31, 2022 $105.41K
Eps Diluted Q3 2023 · Dec 31, 2022 −$0.01
Eps Diluted Q3 2023 · Dec 31, 2022 −$0.02
Eps Diluted Q3 2023 · Dec 31, 2021 $0.01
Eps Diluted Q3 2023 · Dec 31, 2021 $0.00
Eps Basic Q3 2023 · Dec 31, 2022 −$0.01
Eps Basic Q3 2023 · Dec 31, 2022 −$0.02
Eps Basic Q3 2023 · Dec 31, 2021 $0.01
Eps Basic Q3 2023 · Dec 31, 2021 $0.00
Revenue Q3 2023 · Dec 31, 2022 $0
Revenue Q3 2023 · Dec 31, 2022 $0
Revenue Q3 2023 · Dec 31, 2021 $1M
Revenue Q3 2023 · Dec 31, 2021 $1M
Operating Cash Flow Q3 2023 · Dec 31, 2021 $120.8K
Stockholders Equity Q3 2023 · Dec 31, 2021 −$447.99K
Stockholders Equity Q3 2023 · Sep 30, 2021 −$1.05M
Stockholders Equity Q3 2023 · Jun 30, 2021 −$834.28K
Stockholders Equity Q3 2023 · Mar 31, 2021 −$472.51K
Rd Expense restated Q3 2023 · Dec 31, 2021 $41K
Rd Expense restated Q3 2023 · Dec 31, 2021 $139.53K
Net Income Q3 2023 · Dec 31, 2021 $597.32K
Net Income Q3 2023 · Dec 31, 2021 −$63.78K
Net Income Q3 2023 · Sep 30, 2021 −$211.03K
Net Income Q3 2023 · Jun 30, 2021 −$450.08K
Operating Income Q3 2023 · Dec 31, 2021 $630.98K
Operating Income Q3 2023 · Dec 31, 2021 −$42.07K